Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: Opportunities for therapeutic intervention

Leukemia

Volumn 28, Issue 1, 2014, Pages 15-33

  McCubrey, J A ^a   Steelman, L S ^a   Bertrand, F E ^a   Davis, N M ^a   Abrams, S L ^a   Montalto, G ^b   D'Assoro, A B ^c   Libra, M ^d   Nicoletti, F ^d   Maestro, R ^e   Basecke, J ^f,g   Cocco, L ^h   Cervello, M ⁱ   Martelli, A M ^h,j  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

^c MAYO GRADUATE SCHOOL   (United States)

^d UNIVERSITY OF CATANIA   (Italy)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

^g Department of Hematology and Oncology   (Germany)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ CNR   (Italy)

^j RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

more..

Author keywords

Akt; GSK 3; leukemia stem cells; targeted therapy; therapy resistance; Wnt b catenin

Indexed keywords

BETA ARRESTIN 2; BETA CATENIN; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; HAMARTIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN INHIBITOR; RAF PROTEIN; RAS PROTEIN; RNA BINDING PROTEIN; TUBERIN; WNT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; ENZYME ACTIVITY; ENZYME REGULATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; LEUKEMOGENESIS; MULTIPLE MYELOMA; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RNA SPLICING; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STEM CELL; WNT SIGNALING PATHWAY;

ANIMALS; BETA CATENIN; CARCINOGENESIS; GLYCOGEN SYNTHASE KINASE 3; HEMATOPOIESIS; HUMANS; LEUKEMIA; WNT PROTEINS;

EID: 84891841884     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.184     Document Type: Review

References (155)

1. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980; 107: 519-527.
2. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990; 9: 2431-2438.
3. Gao C, Holscher C, Liu Y, Li L. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev Neurosci 2012; 23: 1-11.
4. Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Role of glycogen synthase kinase-3[beta] in cardioprotection. Circ Res 2009; 104: 1240-1252.
5. Shimura T. Acquired radioresistance of cancer and the AKT/GSK3beta/cyclin D1 overexpression cycle. J Radiat Res 2011; 52: 539-544.
6. Fu Y, Hu D, Qiu J, Xie X, Ye F, Lu WG. Overexpression of glycogen synthase kinase-3 in ovarian carcinoma cells with acquired paclitaxel resistance. Int J Gynecol Cancer 2011; 21: 439-444.
7. Kawazoe H, Bilim VN, Ugolkov AV, Yuuki K, Naito S, Nagaoka A et al. GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC). Biochem Biophys Res Commun 2012; 423: 490-495.
8. Welham MJ, Kingham E, Sanchez-Ripoll Y, Kumpfmueller B, Storm M, Bone H. Controlling embryonic stem cell proliferation and pluripotency: the role of PI3K-and GSK-3-dependent signalling. Biochem Soc Trans 2011; 39: 674-678.
9. Gandillet A, Park S, Lassailly F, Griessinger E, Vargaftig J, Filby A et al. Heterogeneous sensitivity of human acute myeloid leukemia to catenin down-modulation. Leukemia 2011; 25: 770-780.
10. Van Coppernolle S, Vanhee S, Verstichel G, Snauwaert S, van der Spek A, Velghe I et al. Notch induces human T-cell receptor\+thymocytes to differentiate along a parallel, highly proliferative and bipotent CD4 CD8 double-positive pathway. Leukemia 2012; 26: 127-138.
11. Wickremasinghe RG, Prentice AG, Steele AJ. p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies. Leukemia 2011; 25: 1400-1407.
12. Masiero M, Minuzzo S, Pusceddu I, Moserle L, Persano L, Agnusdei V et al. Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells. Leukemia 2011; 25: 588-598.
13. Schwarzer R, Dorken B, Jundt F. Notch is an essential upstream regulator of NF-kB and is relevant for survival of Hodgkin and Reed-Sternberg cells. Leukemia 2012; 26: 806-813.
14. Blackburn JS, Liu S, Raiser DM, Martinez SA, Feng H, Meeker ND et al. Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency. Leukemia 2012; 26: 2069-2078.
15. Xu D, Hu J, Xu S, De Bruyne E, Menu E, Van Camp B et al. Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138\+ MM-cell proliferation. Leukemia 2012; 26: 1402-1405.
16. Xu S, Evans H, Buckle C, De Veirman K, Hu J, Xu D et al. Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. Leukemia 2012; 26: 2546-2549.
17. Shepherd C, Banerjee L, Cheung CW, Mansour MR, Jenkinson S, Gale RE et al. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. Leukemia 2013; 27: 650-660.
18. Wang R, Xia L, Gabrilove J, Waxman S, Jing Y. Downregulation of Mcl-1 through GSK-3 activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. Leukemia 2013; 27: 315-324.
19. Si J, Mueller L, Collins SJ. GSK3 inhibitors enhance retinoic acid receptor activity and induce the differentiation of retinoic acid-sensitive myeloid leukemia cells. Leukemia 2011; 25: 1914-1918.
20. Luis TC, Ichii M, Brugman MH, Kincade P, Staal FJ. Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development. Leukemia 2012; 26: 414-421.
21. Mar BG, Amakye D, Aifantis I, Buonamici S. The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis. Leukemia 2011; 25: 1665-1673.
22. Pajcini KV, Speck NA, Pear WS. Notch signaling in mammalian hematopoietic stem cells. Leukemia 2011; 25: 1525-1532.
23. Patel S, Woodgett J. Glycogen synthase kinase-3 and cancer: good cop, bad cop Cancer Cell 2008; 14: 351-353.
24. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116: 1175-1186. (Pubitemid 36410657)
25. Sutherland C. What are the bona fide GSK3 substrates Int J Alzheimers Dis 2011; 2011: Article ID 505607; 23 pages.
26. Kockeritz L, Doble B, Patel S, Woodgett JR. Glycogen synthase kinase-3-an overview of an over-achieving protein kinase. Curr Drug Targets 2006; 7: 1377-1388. (Pubitemid 44718298)
27. Cole A, Frame S, Cohen P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem J 2004; 377: 249-255. (Pubitemid 38114452)
28. Bhat RV, Shanley J, Correll MP, Fieles WE, Keith RA, Scott CW et al. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci USA 2000; 97: 11074-11079.
29. Bijur GN, Jope RS. Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J Biol Chem 2001; 276: 37436-37442.
30. Hartigan JA, Xiong WC, Johnson GV. Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2. Biochem Biophys Res Commun 2001; 284: 485-489. (Pubitemid 32918003)
31. Lesort M, Jope RS, Johnson GV. Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J Neurochem 1999; 72: 576-584. (Pubitemid 29055219)
32. Thornton TM, Pedraza-Alva G, Deng B, Wood CD, Aronshtam A, Clements JL et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 2008; 320: 667-670. (Pubitemid 351928349)
33. Bennecib M, Gong CX, Grundke-Iqbal I, Iqbal K. Role of protein phosphatase-2A and-1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett 2000; 485: 87-93.
34. Shin S, Wolgamott L, Yu Y, Blenis J, Yoon SO. Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc Natl Acad Sci USA 2011; 108: 1204-1213.
35. McQueen J, van Dyk D, Young B, Loewen C, Measday V. The Mck1 GSK-3 kinase inhibits the activity of Clb2-Cdk1 post-nuclear division. Cell Cycle 2012; 11: 3421-3432.
36. Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008; 455: 1205-1209.
37. Rossig L, Badorff C, Holzmann Y, Zeiher AM, Dimmeler S. Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J Biol Chem 2002; 277: 9684-9689. (Pubitemid 34968067)
38. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12: 3499-3511. (Pubitemid 28553242)
39. Welcker M, Singer J, Loeb KR, Grim J, Bloecher A, Gurien-West M et al. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell 2003; 12: 381-392. (Pubitemid 37238925)
40. Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer Mol Cancer 2010; 9: 144.
41. Bianchi M, De Lucchini S, Marin O, Turner DL, Hanks SK, Villa-Moruzzi E. Regulation of FAK Ser-722 phosphorylation and kinase activity by GSK3 and PP1 during cell spreading and migration. Biochem J 2005; 391: 359-370. (Pubitemid 41532434)
42. Belkhiri A, Dar AA, Zaika A, Kelley M, El-Rifai W. t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism. Cancer Res 2008; 68: 395-403. (Pubitemid 351380066)
43. Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY et al. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 2007; 27: 4006-4017. (Pubitemid 47010998)
44. Nifoussi SK, Vrana JA, Domina AM, De Biasio A, Gui J, Gregory MA et al. Thr 163 phosphorylation causes Mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancer. PLoS One 2012; 7: e47060.
45. Zhao Y, Altman BJ, Coloff JL, Herman CE, Jacobs SR, Wieman HL et al. Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol Cell Biol 2007; 27: 4328-4339. (Pubitemid 46906557)
46. Zhou F, Zhang L, van Laar T, van Dam H, Ten Dijke P. GSK3beta inactivation induces apoptosis of leukemia cells by repressing the function of c-Myb. Mol Biol Cell 2011; 22: 3533-3540.
47. Ross SE, Erickson RL, Hemati N, MacDougald OA. Glycogen synthase kinase 3 is an insulin-regulated C/EBPalpha kinase. Mol Cell Biol 1999; 19: 8433-8441. (Pubitemid 30414037)
48. MacAulay K, Doble BW, Patel S, Hansotia T, Sinclair EM, Drucker DJ et al. Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab 2007; 6: 329-337. (Pubitemid 47450185)
49. Kaidanovich-Beilin O, Lipina TV, Takao K, van Eede M, Hattori S, Laliberté C et al. Abnormalities in brain structure and behavior in GSK-3alpha mutant mice. Mol Brain 2009; 2: 35.
50. Soutar MP, Kim WY, Williamson R, Peggie M, Hastie CJ, McLauchlan H et al. Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain. Neurochem 2010; 115: 974-983.
51. Banerji V, Frumm SM, Ross KN, Li LS, Schinzel AC, Hahn CK et al. The intersection of genetic and chemical genomic screens identifies GSK-3alpha as a target in human acute myeloid leukemia. J Clin Invest 2012; 122: 935-947.
52. Bolzoni M, Donofrio G, Storti P, Guasco D, Toscani D, Lazzaretti M et al. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells. Leukemia 2013; 27: 451-463.
53. Morgan RG, Pearn L, Liddiard K, Pumford SL, Burnett AK, Tonks A et al. b-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of catenin. Leukemia 2013; 27: 336-343.
54. Liu P, Xu B, Shen W, Zhu H, Wu W, Fu Y, Chen H et al. Dysregulation of TNF-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1. Leukemia 2012; 26: 1293-1300.
55. Stengel C, Cheung CW, Quinn J, Yong K, Khwaja A. Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype. Leukemia 2012; 26: 1761-1770.
56. Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 2012; 26: 1195-1202.
57. Rao E, Jiang C, Ji M, Huang X, Iqbal J, Lenz G, Wright G et al. The miRNA-17B92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 2012; 26: 1064-1072.
58. Fuka G, Kantner HP, Grausenburger R, Inthal A, Bauer E, Krapf G et al. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts. Leukemia 2012; 26: 927-933.
59. Fruchon S, Kheirallah S, Al Saati T, Ysebaert L, Laurent C, Leseux L, Fournie JJ et al. Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis. Leukemia 2012; 26: 795-805.
60. Ramakrishnan V, Ansell S, Haug J, Grote D, Kimlinger T, Stenson M et al. MRK003, a-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. Leukemia 2012; 26: 340-348.
61. Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia 2012; 26: 2336-2342.
62. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B et al. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 2011; 146: 697-708.
63. Grimaldi C, Chiarini F, Tabellini G, Ricci F, Tazzari PL, Battistelli M et al. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia 2012; 26: 91-100.
64. Martelli AM, Evangelisti C, Chappell W, Abrams SL, Bäsecke J, Stivala F et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011; 25: 1064-1079.
65. Wang H, Brown J, Gu Z, Garcia CA, Liang R, Alard P et al. Convergence of the mammalian target of rapamycin complex 1-and glycogen synthase kinase 3-b-signaling pathways regulates the innate inflammatory response. J Immunol 2011; 186: 5217-5226.
66. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006; 126: 955-968. (Pubitemid 44310775)
67. Clevers H, Nusse R. Wnt/b-catenin signaling and disease. Cell 2012; 149: 1192-1205.
68. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13: 11-26.
69. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J 1998; 17: 1371-1384. (Pubitemid 28105516)
70. Schwarz-Romond T, Asbrand C, Bakkers J, Kuhl M, Schaeffer HJ, Huelsken J et al. The ankyrin repeat protein diversin recruits casein kinase I epsilon to the b-catenin degradation complex and acts in both canonical Wnt and Wnt/JNK signaling. Genes Dev 2002; 16: 2073-2084.
71. Ferkey DM, Kimelman D. Glycogen synthase kinase-3 beta mutagenesis identifies a common binding domain for GBP and Axin. J Biol Chem 2002; 277: 16147-16152. (Pubitemid 34967901)
72. Franca-Koh J, Yeo M, Fraser E, Young N, Dale TC. The regulation of glycogen synthase kinase-3 nuclear export by Frat/GBP. J Biol Chem 2002; 277: 43844-43848. (Pubitemid 36157806)
73. Ding VW, Chen RH, McCormick F. Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J Biol Chem 2000; 275: 32475-32481.
74. Yuan H, Mao J, Li L, Wu D. Suppression of glycogen synthase kinase activity is not sufficient for leukemia enhancer factor-1 activation. J Biol Chem 1999; 274: 30419-30423.
75. Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R et al. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 2005; 438: 873-877. (Pubitemid 41753071)
76. Davidson G, Wu W, Shen J, Bilic J, Fenger U, Stannek P et al. Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature 2005; 438: 867-872. (Pubitemid 41753070)
77. Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C et al. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science 2007; 316: 1043-1046. (Pubitemid 46799493)
78. Valvezan AJ, Zhang F, Diehl JA, Klein PS. Adenomatous polyposis coli (APC) regulates multiple signaling pathways by enhancing glycogen synthase kinase-3 (GSK-3) activity. J Biol Chem 2012; 287: 3823-3832.
79. Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U et al. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 2002; 22: 1184-1193. (Pubitemid 34094854)
80. Niida A, Hiroko T, Kasai M, Furukawa Y, Nakamura Y, Suzuki Y et al. DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene 2004; 23: 8520-8526. (Pubitemid 39540802)
81. Yoshioka S, King ML, Ran S, Okuda H, MacLean 2nd JA, McAsey ME et al. WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/b-catenin pathway. Mol Cancer Res 2012; 10: 469-482.
82. Ochoa-Hernández AB, Ramos-Solano M, Meza-Canales ID, Garća-Castro B, Rosales-Reynoso MA, Rosales-Aviña JA et al. Peripheral T-lymphocytes express WNT7A and its restoration in leukemia-derived lymphoblasts inhibits cell proliferation. BMC Cancer 2012; 12: 60.
83. Bitler BG, Nicodemus JP, Li H, Cai Q, Wu H, Hua X et al. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res 2011; 71: 6184-6194
84. Kremenevskaja N, von Wasielewski R, Rao AS, Schöfl C, Andersson T, Brabant G. Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 2005; 24: 2144-2154. (Pubitemid 40516581)
85. Liang H, Chen Q, Coles AH, Anderson SJ, Pihan G, Bradley A et al. Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 2003; 4: 349-360. (Pubitemid 37491096)
86. Wu QL, Zierold C, Ranheim EA. Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia. Blood 2009; 113: 3031-3039.
87. Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D et al. b-catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010; 18: 606-618.
88. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-667. (Pubitemid 39063268)
89. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003; 423: 448-452. (Pubitemid 36626997)
90. Duncan AW, Rattis FM, DiMascio LN, Congdon KL, Pazianos G, Zhao C et al. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 2005; 6: 314-322. (Pubitemid 41724769)
91. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003; 423: 409-414. (Pubitemid 36626987)
92. ten Berge D, Kurek D, Blauwkamp T, Koole W, Maas A, Eroglu E et al. Embryonic stem cells require Wnt proteins to prevent differentiation to epiblast stem cells. Nat Cell Biol 2011; 13: 1070-1075.
93. Huang J, Zhang Y, Bersenev A, O'Brien WT, Tong W, Emerson SG et al. Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. J Clin Invest 2009; 119: 3519-3529.
94. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441: 475-482. (Pubitemid 44050144)
95. Chen C, Liu Y, Liu R, Ikenoue T, Guan KL, Liu Y et al. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med 2008; 205: 2397-2408.
96. Lee JY, Nakada D, Yilmaz OH, Tothova Z, Joseph NM, Lim MS et al. mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell 2010; 7: 593-605.
97. Huang J, Zhang Y, Bersenev A, O'Brien WT, Tong W, Emerson SG et al. Pivotal role for glycogen synthase kinase-3 hematopoietic stem cell homeostasis in mice. J Clin Invest 2009; 119: 3519-3529.
98. Gurumurthy S, Xie SZ, Alagesan B, Kim J, Yusuf RZ, Saez B et al. The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature 2010; 468: 659-663.
99. Huang J, Nguyen-McCarty M, Hexner EO, Danet-Desnoyers G, Klein PS. Maintenance of hematopoietic stem cells through regulation of Wnt and mTOR pathways. Nat Med 2012; 18: 1778-1785.
100. Ito K, Carracedo A, Weiss D, Arai F, Ala U, Avigan DE et al. A PML-PPAR-delta pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med 2012; 18: 1350-1358.
101. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008; 453: 1072-1078. (Pubitemid 351871736)
102. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004; 10: 55-63. (Pubitemid 38524699)
103. Doble BW, Patel S, Wood GA, Kockeritz LK, Woodgett JR. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell 2007; 12: 957-971. (Pubitemid 46805920)
104. Jeannet G, Scheller M, Scarpellino L, Duboux S, Gardiol N, Back J et al. Long-term, multilineage hematopoiesis occurs in the combined absence of beta-catenin and gamma-catenin. Blood 2008; 111: 142-149.
105. Majeti R, Becker MW, Tian Q, Lee TL, Yan X, Liu R et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci USA 2009; 106: 3396-3401.
106. Stein RS, Vogler WR, Lefante J. Failure of lithium to limit neutropenia significantly during induction therapy of acute myelogenous leukemia. A Southeastern Cancer Study Group study. Am J Clin Oncol 1984; 7: 365-369. (Pubitemid 14067202)
107. Gupta K, Gulen F, Sun L, Aguilera R, Chakrabarti A, Kiselar J et al. GSK3 is a regulator of RAR-mediated differentiation. Leukemia 2012; 26: 1277-1285.
108. Heidel FH, Bullinger L, Feng Z, Zu W, Neff TA, Stein L et al. Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 2012; 10: 412-424.
109. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007; 12: 528-541. (Pubitemid 350199070)
110. Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012; 21: 266-281.
111. Holloway KR, Calhoun TN, Saxena M, Metoyer CF, Kandler EF, Rivera CA et al. SIRT1 regulates dishevelled proteins and promotes transient and constitutive Wnt signaling. Proc Natl Acad Sci USA 2010; 107: 9216-9221.
112. Gu Y, Chen T, Meng Z, Gan Y, Xu X, Lou G et al. CaMKIIgamma, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine. Blood 2012; 120: 4829-4839.
113. Abrahamsson AE, Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA 2009; 106: 3925-3929.
114. MacNicol MC, Cragle CE, MacNicol AM. Context-dependent regulation of Musashi-mediated mRNA translation and cell cycle regulation. Cell Cycle 2011; 10: 39-44.
115. Kanwar SS, Yu Y, Nautiyal J, Patel BB, Majumdar AP. The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer 2010; 9: 212.
116. Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 2010; 466: 765-768.
117. Espinosa L, Inglé s-Esteve J, Aguilera C, Bigas A. Phosphorylation by glycogen synthase kinase-3 beta down-regulates Notch activity, a link for Notch and Wnt pathways. J Biol Chem 2003; 278: 32227-32235. (Pubitemid 37048415)
118. Colaluca IN, Tosoni D, Nuciforo P, Senic-Matuglia F, Galimberti V, Viale G et al. NUMB controls p53 tumour suppressor activity. Nature 2008; 451: 76-80.
119. Pece S, Confalonieri S, Romano PR, Di Fiore PP. NUMB-ing down cancer by more than just a NOTCH. Biochim Biophys Acta 2011; 1815: 26-43.
120. Fereshteh M, Ito T, Kovacs JJ, Zhao C, Kwon HY, Tornini V et al. b-Arrestin2 mediates the initiation and progression of myeloid leukemia. Proc Natl Acad Sci USA 2012; 109: 12532-12537.
121. Chen W, ten Berge D, Brown J, Ahn S, Hu LA, Miller WE et al. Dishevelled 2 recruits beta-arrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4. Science 2003; 301: 1391-1394. (Pubitemid 37075817)
122. O'Brien WT, Huang J, Buccafusca R, Garskof J, Valvezan AJ, Berry GT et al. Glycogen synthase kinase-3 is essential for b-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J Clin Invest 2011; 121: 3756-3762.
123. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 1999; 96: 8745-8750. (Pubitemid 29354862)
124. Yamamoto K, Nakamura Y, Saito K, Furusawa S. Expression of the NUP98/HOXA9 fusion transcript in the blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia with t(7;11)(p15;p15). Br J Haematol 2000; 109: 423-426. (Pubitemid 30350728)
125. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 327: 1650-1653.
126. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005; 310: 1504-1510. (Pubitemid 41746348)
127. Coluccia AM, Vacca A, Duñ ach M, Mologni L, Redaelli S, Bustos VH et al. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 2007; 26: 1456-1466.
128. Reddiconto G, Toto C, Palamà I, De Leo S, de Luca E, De Matteis S et al. Targeting of GSK-3b promotes imatinib-mediated apoptosis in quiescent CD34\+ chronic myeloid leukemia progenitors, preserving normal stem cells. Blood 2012; 119: 2335-2345.
129. Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007; 110: 735-742. (Pubitemid 47105412)
130. Piazza F, Manni S, Tubi LQ, Montini B, Pavan L, Colpo A et al. Glycogen synthase kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. BMC Cancer 2010; 10: 526.
131. Ikegame A, Ozaki S, Tsuji D, Harada T, Fujii S, Nakamura S et al. Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors. Leukemia 2012; 26: 2124-2134.
132. G-Amlak M, Uddin S, Mahmud D, Damacela I, Lavelle D, Ahmed M et al. Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. Biochem Biophys Res Commun 2002; 297: 760-764. (Pubitemid 35230315)
133. Rocques N, Abou Zeid N, Sii-Felice K, Lecoin L, Felder-Schmittbuhl MP, Eychène A et al. GSK-3-mediated phosphorylation enhances Maf-transforming activity. Mol Cell 2007; 28: 584-597. (Pubitemid 350137803)
134. Gunn WG, Krause U, Lee N, Gregory CA. Pharmaceutical inhibition of glycogen synthetase kinase-3beta reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model. Blood 2011; 117: 1641-1651.
135. Busino L, Millman SE, Scotto L, Kyratsous CA, Basrur V, O'Connor O et al. Fbxw7alpha and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol 2012; 14: 375-385.
136. Ricci P, Bandini G, Franchi P, Motta MR, Visani G, Calamandrei G. Haematological effects of lithium carbonate: a study in 56 psychiatric patients. Haematologica 1981; 66: 627-633. (Pubitemid 12200243)
137. Ballin A, Lehman D, Sirota P, Litvinjuk U, Meytes D. Increased number of peripheral blood CD34\+ cells in lithium-treated patients. Br J Haematol 1998; 100: 219-221. (Pubitemid 28051863)
138. Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VM, Klein PS. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol 1997; 185: 82-91. (Pubitemid 27244219)
139. Ougolkov AV, Billadeau DD. Inhibition of glycogen synthase kinase-3. Methods Mol Biol 2008; 468: 67-75.
140. Mirlashari MR, Randen I, Kjeldsen-Kragh J. Glycogen synthase kinase-3 (GSK-3) inhibition induces apoptosis in leukemic cells through mitochondria-dependent pathway. Leuk Res 2012; 36: 499-508.
141. Huang HS, Liu ZM, Cheng YL. Involvement of glycogen synthase kinase-3b in arsenic trioxide-induced p21 expression. Toxicol Sci 2011; 121: 101-109.
142. Alao JP, Stavropoulou AV, Lam EW, Coombes RC. Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells. Mol Cancer 2006; 5: 40.
143. Bakre MM, Hoi A, Mong JC, Koh YY, Wong KY, Stanton LW. Generation of multipotential mesendodermal progenitors from mouse embryonic stem cells via sustained Wnt pathway activation. J Biol Chem 2007; 282: 31703-31712. (Pubitemid 350044886)
144. Riobo NA, Lu K, Ai X, Haines GM, Emerson Jr. CP. Phosphoinositide 3-kinase and Akt are essential for Sonic hedgehog signaling. Proc Natl Acad Sci USA 2006; 103: 4505-4510.
145. Bone HK, Damiano T, Bartlett S, Perry A, Letchford J, Sanchez Ripoli Y et al. Involvement of GSK-3 in regulation of murine embryonic stem cell self-renewal revealed by a series of bisindolylmaleimides. Chem Biol 2009; 16: 15-27.
146. Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011; 25: 1080-1094.
147. Silva A, Girio A, Cebola I, Santos CI, Antunes F, Barata JT. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells. Leukemia 2011; 25: 960-967.
148. Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia 2011; 25: 1182-1188.
149. Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 2011; 25: 781-791.
150. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009; 5: 100-107.
151. Song S, Christova T, Perusini S, Alizadeh S, Bao RY, Miller BW et al. Wnt inhibitor screen reveals iron dependence of beta-catenin signaling in cancers. Cancer Res 2011; 71: 7628-7639.
152. Kovacevic Z, Kalinowski DS, Lovejoy DB, Yu Y, Suryo Rahmanto Y, Sharpe PC et al. The medicinal chemistry of novel iron chelators for the treatment of cancer. Curr Top Med Chem 2011; 11: 483-499.
153. Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP et al. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res 2008; 68: 1213-1220. (Pubitemid 351272241)
154. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009; 461: 614-620.
155. Tanaka K, Okabayashi K, Asashima M, Perrimon N, Kadowaki T. The evolutionarily conserved porcupine gene family is involved in the processing of the Wnt family. Eur J Biochem 2000; 267: 4300-4311. (Pubitemid 30436127)